Overview
Kallyope Inc. is a biotechnology company headquartered in New York, NY 10016[1][7]. The company leverages insights into neural signaling pathways to develop medicines for migraine treatment[2][3]. Kallyope's lead asset is elismetrep (K-304), a novel oral TRPM8 channel blocker in Phase 3 development for acute migraine treatment[4]. A Phase 2b study involving nearly 450 patients supported the drug's clinical benefit[5], with positive results announced on December 8, 2025[8]. The Phase 3 program comprises two pivotal trials and a long-term safety study[5]. In January 2026, Kallyope announced strategic priorities for a migraine and metabolism portfolio built on its neural circuits platform[9]. The company's investors include Alexandria Real Estate, Bill Gates, Casdin Capital, Illumina Ventures, Lux Capital, Mubadala, Polaris Partners, and others[6].
Kallyope Inc. is located in New York, NY 10016 [1]
Kallyope's lead asset elismetrep (K-304) is described as a novel, oral, highly selective TRPM8 channel blocker in Phase 3 development for the acute treatment of migraine. [4]
Kallyope Inc. lists its address as New York, NY 10016. [7]
Business address: 430 East 29th Street, New York, New York, 10016. [11]
Growth & traction
Kallyope says its Phase 2b study of elismetrep in nearly 450 patients strongly supported the drug's clinical benefit, and its Phase 3 program comprises two pivotal trials plus a long-term safety study now underway. [5]
Kallyope announced positive Phase 2b results for elismetrep on December 8, 2025, presented the data at the American Academy of Neurology Annual Meeting on April 22, 2026, and presented new TRPM8 data at the American Headache Society's 68th Annual Scientific Meeting on June 4, 2026. [8]
Funding history
Kallyope lists its investors as Alexandria Real Estate, Bill Gates, Casdin Capital, DNS Capital, Euclidean Capital, Hartford HealthCare, Illumina Ventures, Lux Capital, Mubadala, Polaris Partners, StepStone, Tao Capital Partners, The Column Group and Two Sigma Ventures. [6]
In the news
Recent developments
- Kallyope's careers page states there are no career opportunities available at this time.[10]
Focus
- On January 7, 2026 Kallyope announced 2026 strategic priorities for a migraine and metabolism portfolio built on its novel neural circuits platform.[9]
Something wrong or missing? Send an update. Fixed within 24 hours.